First MAb approved for treatment of metastatic breast cancer.

T. L. Brenner; V. R. Adams

doi:10.1016/s1086-5802(16)30498-3

First MAb approved for treatment of metastatic breast cancer.

Producción científica: Review article › revisión exhaustiva

39 Citas (Scopus)

Idioma original	English
Páginas (desde-hasta)	236-238
Número de páginas	3
Publicación	Journal of the American Pharmaceutical Association (Washington,D.C. : 1996)
Volumen	39
N.º	2
DOI	https://doi.org/10.1016/s1086-5802(16)30498-3
Estado	Published - 1999

Nota bibliográfica

Funding Information:
is developed by the Ameri can Pharmaceutical Asso ciation, edited by Peggy Piascik, PhD, University of Kentucky College of Pharmacy, and supported by an educational grant from Amgen Inc. The views expressed are not neces sarily those of Amgen.

Financiación

is developed by the Ameri can Pharmaceutical Asso ciation, edited by Peggy Piascik, PhD, University of Kentucky College of Pharmacy, and supported by an educational grant from Amgen Inc. The views expressed are not neces sarily those of Amgen.

Financiadores	Número del financiador
Ameri can Pharmaceutical Asso ciation

ASJC Scopus subject areas

Pharmaceutical Science

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1016/s1086-5802(16)30498-3

Otros archivos y enlaces

Citar esto

@article{af98ab73861f43cc828a1008073bd25f,

title = "First MAb approved for treatment of metastatic breast cancer.",

author = "Brenner, \{T. L.\} and Adams, \{V. R.\}",

note = "Funding Information: is developed by the Ameri can Pharmaceutical Asso ciation, edited by Peggy Piascik, PhD, University of Kentucky College of Pharmacy, and supported by an educational grant from Amgen Inc. The views expressed are not neces sarily those of Amgen.",

year = "1999",

doi = "10.1016/s1086-5802(16)30498-3",

language = "English",

volume = "39",

pages = "236--238",

number = "2",

}

TY - JOUR

T1 - First MAb approved for treatment of metastatic breast cancer.

AU - Brenner, T. L.

AU - Adams, V. R.

N1 - Funding Information: is developed by the Ameri can Pharmaceutical Asso ciation, edited by Peggy Piascik, PhD, University of Kentucky College of Pharmacy, and supported by an educational grant from Amgen Inc. The views expressed are not neces sarily those of Amgen.

PY - 1999

Y1 - 1999

UR - https://www.scopus.com/pages/publications/0033093978

UR - https://www.scopus.com/inward/citedby.url?scp=0033093978&partnerID=8YFLogxK

U2 - 10.1016/s1086-5802(16)30498-3

DO - 10.1016/s1086-5802(16)30498-3

M3 - Review article

C2 - 10079656

AN - SCOPUS:0033093978

SN - 1086-5802

VL - 39

SP - 236

EP - 238

JO - Journal of the American Pharmaceutical Association (Washington,D.C. : 1996)

JF - Journal of the American Pharmaceutical Association (Washington,D.C. : 1996)

IS - 2

ER -

First MAb approved for treatment of metastatic breast cancer.

Nota bibliográfica

Financiación

ASJC Scopus subject areas

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto